- Home
- ALZN
ALZN
Alzamend Neuro Inc.
as 10-04-2024 4:00pm EST
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 6.9M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 271.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $34.50 | Next Earning Date: | 09-11-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Alzamend Neuro Inc. (ALZN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AULT MILTON C III | ALZN | Director10% Owner | Aug 6 '24 | Buy | $2.75 | 75 | $206.25 | 77,268 | |
| AULT MILTON C III | ALZN | Director10% Owner | Jul 31 '24 | Buy | $3.74 | 25 | $93.42 | 77,268 |
Latest Alzamend Neuro Inc. News
ALZN Breaking Stock News: Dive into ALZN Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Alzamend Neuro Issues Letter to Stockholders
MT Newswires
2 months ago
Top Midday Gainers
MT Newswires
2 months ago
Alzamend Neuro Enters Partnership for Phase II Clinical Trial of Potential Lithium Therapeutic Drug for Post-Traumatic Stress Disorder; Shares Soar
Business Wire
2 months ago
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Business Wire
2 months ago
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Business Wire
2 months ago
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Clinical Trials Arena
2 months ago
Alzamend Neuro partners with Mass General for Alzheimer’s treatment trial
Benzinga
2 months ago
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
Compare ALZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALZN Alzamend Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.